Analysts Set Repligen Co. (NASDAQ:RGEN) Target Price at $181.00

Shares of Repligen Co. (NASDAQ:RGEN) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $181.00.

A number of equities research analysts have commented on RGEN shares. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Royal Bank of Canada lifted their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Repligen in a report on Friday, February 21st.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently modified their holdings of the business. UMB Bank n.a. raised its position in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the period. First Turn Management LLC bought a new stake in shares of Repligen in the third quarter valued at approximately $13,202,000. Thrivent Financial for Lutherans raised its position in shares of Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after purchasing an additional 36,773 shares during the period. Geneva Capital Management LLC raised its position in shares of Repligen by 8.5% in the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after purchasing an additional 10,908 shares during the period. Finally, TimesSquare Capital Management LLC raised its position in shares of Repligen by 14.6% in the third quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock valued at $41,019,000 after purchasing an additional 35,115 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 1.8 %

NASDAQ:RGEN opened at $157.67 on Monday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.83 billion, a price-to-earnings ratio of -309.16, a PEG ratio of 4.54 and a beta of 0.99. The firm has a fifty day simple moving average of $156.74 and a two-hundred day simple moving average of $148.54. Repligen has a 12 month low of $113.50 and a 12 month high of $203.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Analysts expect that Repligen will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.